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Abstract 
Proteinuria was observed in 27% of 153 patients taking tenofovir for more than one year. Concomitant 
protease inhibitor therapy and cumulative tenofovir exposure were independently associated with  
proteinuria in this cohort. Proteinuria was reversible in 11 of 12 patients who ceased tenofovir because 
of proteinuria without altering other medications. Clinicians should be aware that tenofovir cancause 
reversible proteinuria in patients with HIV.  
 
Keywords 
Proteinuria, Chronic Kidney Disease, Tenofovir 
 2
Chronic Kidney Disease (CKD) is associated with increased mortality and cardiovascular disease in 
patients with HIV.1,2 Cumulative exposure to tenofovir and some protease inhibitors has been 
associated with CKD defined according to reductions in estimates of glomerular filtration rate (GFR).3  
Proteinuria can precede reductions in GFR and represents significant renal pathology including 
proximal tubular dysfunction. Proteinuria has been shown to predict all cause mortality in subjects with 
untreated and treated HIV.4 Proteinuria has been associated with tenofovir therapy although the 
prevalence, predictors and outcomes of persons who develop proteinuria in association with tenofovir 
therapy are not well described.5  
 
All patients undergo annual proteinuria screening in our clinic. This is performed by calculating the 
protein:creatinine ratio on a random urine specimen. The medical records of patients who received 
tenofovir for more than one year were retrospectively reviewed. Age, gender, HIV viral load, current 
CD4 count, antiretroviral status at time of initiation of tenofovir (naïve or experienced); concomitant 
antiretroviral therapy (ART), duration of tenofovir therapy, estimated glomerular filtration rate (eGFR) 
calculated by the Modification of Diet in Renal Disease equation (values over 90 mL/min/1.73m2 
reported as >90), non-fasting serum phosphate (PO4), and urine protein:creatinine ratio (UPCR) were 
collated. Proteinuria was defined as a UPCR >15 g/mol on repeat testing having excluded urinary tract 
infection. Hypertension, diabetes and body mass index were not well recorded and have not been 
included in this analysis. Factors associated with proteinuria were examined using univariate (student t 
test for continuous variables and chi square test for categorical variables) and multivariate analyses. 
Changes in UPCR were compared in patients who ceased tenofovir because of proteinuria with those of 
patients who continued tenofovir despite proteinuria. 
 
One hundred and fifty three patients were identified and all were included in this analysis. The 
characteristics of the patients are shown in Table 1. All patients had a viral load below the limit of 
detection of 40 copies/mL. Forty-two (27%) patients had proteinuria (mean UPCR 38 SD 34). 
Multivariate analyses indicated that longer duration of tenofovir use (p=0.006, OR 1.29 per year, 95% 
confidence interval 1.08-1.54) and concomitant protease inhibitor therapy (p=0.004, OR 7.36, 95% 
confidence interval 1.88-28.9) were associated with proteinuria. Age, gender, current CD4 count or 
treatment status at the time initiation of tenofovir did not predict proteinuria in multivariate analyses. 
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Proteinuria was associated with lower eGFR (median 80.5 v >90 mL/min/1.73m2, approximate OR 
0.91 per mL/min/1.73m2, approximate 95% confidence interval 0.87-0.95) and lower non-fasting 
serum PO4 (mean 0.99 v 1.06 mmol/L p=0.009, OR 0.70 per 0.1 mmol/L increment, 95% confidence 
interval 0.53 – 0.91). However the differences in these parameters between patients with and without 
proteinuria were small and may not be considered to be significant by the clinician. 
 
Twelve patients ceased tenofovir and commenced an alternative nucleoside reverse transcpritase 
inhibitor because of proteinuria. These patients did not alter other medication. In particular they did not 
commence angiotensin converting enzyme inhibitor therapy, other antihypertensive agents, diabetic 
therapy or alter protease inhibitor therapy. Patients who ceased tenofovir because of proteinuria had 
higher mean UPCR prior to ceasing tenofovir than patients with proteinuria who continued tenofovir 
(64 v 28 p=0.03). Proteinuria significantly reduced over a six month period in 11 of 12 patients ceasing 
tenofovir (64 to 14 p=0.001) whereas UPCR did not significantly change over a similar period in 30 
patients continuing tenofovir despite proteinuria. UPCR increased from 71 to 123 in one patient despite 
cessation of tenofovir. This patient was also taking ritonavir boosted darunavir. He was normotensive 
and had a normal fasting blood glucose level and eGFR > 90. His urinary albumin creatinine ratio was 
also increased (87, cf normal <1). No cause has yet been identified for this patient’s proteinuria. 
 
The prevalence of proteinuria among those patients taking tenofovir in our cohort was 27%. We found 
an association between duration of tenofovir therapy and proteinuria and estimated that the odds of 
proteinuria increased by 2% for every month of tenofovir therapy (29% per year). These findings are 
consistent with other studies. The risk of proteinuria increased by 30% per year of exposure to 
tenofovir in one study.6 Another study reported that the incidence of proteinuria in patients taking 
tenofovir was 9% per year.5 The co-administration of protease inhibitor therapy with tenofovir 
increased the odds of proteinuria by seven times in our study. This is consistent with another study.5 
Possible causes of this association include ritonavir inhibition of enzymes involved in tenofovir 
elimination from the kidney.  
 
Tenofovir associated proteinuria was reversible in the majority (11/12) of patients who ceased the drug 
in our cohort. Other studies have not demonstrated such reversibility in renal abnormalities in patients 
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who cease tenofovir. The reasons for this disparity are unclear however it is likely that patients in other 
studies had more pronounced renal dysfunction at the time of tenofovior cessation. The mean eGFR of 
the patients who ceased tenofovir in one study was 51 mL/min/1.73m2 compared with 76.3 
mL/min/1.73m2 in our study. Renal parameters did not improve following tenofovir cessation in 42% 
of patients in this study.  It is interesting to speculate that proteinuria may be an early and reversible 
effect of tenofovir associated renal damage. As hypertension and diabetes were not well documented in 
this cohort we cannot exclude the possibility that the management of these conditions impacted upon 
the improvements of proteinuria in patients ceasing tenofovir because of proteinuria however this 
seems unlikely.  
 
Proteinuria was commonly detected in patients taking tenofovir for more than one year in this cohort. 
The risk of proteinuria increased with longer duration of tenofovir therapy and was greater in persons 
also taking protease inhibitor therapy. Proteinuria was generally observed in the absence of marked 
decreases in either serum phosphate or eGFR. Tenofovir associated proteinuria generally resolved upon 
cessation of the drug. Larger studies are warranted to confirm these initial findings; to describe the 
natural history of tenofovir associated proteinuria; to determine the value of regular proteinuria 
screening in persons taking tenofovir and to address the impact of tenofovir associated nephrotoxicity 
on bone disease.   
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 Patient group 
Mean (SD) or Number (%) 
Analysis 
Univariate Multivariate 
Total group With 
Proteinuria 
Without 
Proteinuria 
p p OR 95% CI 
Number 153 42 (27%) 111 (73%)  
Age (years) 47.7 (9.9) 51.2 (10.5) 46.3 (9.4) 0.01  
male 134 (87.6) 38 (90.5) 96 (86.5)  
ART naïve at 
time of 
initiation of 
tenofovir 
55 (35.9) 14 (33) 41 (36.9) 
CD4/µL 612 (236) 629 (231) 606 (238) 
eGFR* 
mL/min/1.73m2 
eGFR > 90 
88  
(77->90) 
75 (49) 
80.5 
(64.8->90) 
15 (36) 
>90 
(79->90) 
60 (54) 
< 0.001** 
 
0.043 
<0.001** 
 
*** 
0.91 per 
mL/min/1.73m2 
0.87-0.95 
PO4 
mmol/L 
1.04 (0.18) 0.99 (0.18) 1.06 (0.17) <0.001 0.009 0.03 per mmol/L 
0.70 per 0.1 mmol/L 
0.00-0.40 
0.53-0.91 
Duration of 
tenofovir 
(months) 
62.0 (27.7) 74.6 (26.9) 57.2 (26.6) < 0.001 0.006 1.02 per month 
1.29 per year 
1.01-1.04 
1.08-1.54 
 
Concomitant 
protease 
inhibitors 
115 (75) 37 (88) 78 (70) 0.002 0.004 7.36 1.88-28.9 
Table 1: Characteristics of patients with and without proteinuria whilst taking tenofovir. 
* Median (interquartile range) 
** approximate results (treating ‘>90’ values as equal to 90) 
*** not included in multivariate analysis 
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